Trial Profile
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY INVESTIGATING THE EFFICACY AND SAFETY OF MULTIPLE DUPILUMAB DOSE REGIMENS ADMINISTERED AS MONOTHERAPY FOR MAINTAINING TREATMENT RESPONSE IN PATIENTS WITH ATOPIC DERMATITIS
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms LIBERTY AD SOLO-CONTINUE; SOLO-CONTINUE
- Sponsors Regeneron Pharmaceuticals
- 28 Oct 2023 Results comparing the long-term efficacy and safety of lebrikizumab every 4 weeks (Q4W) and dupilumab every week or every 2 weeks (QW/Q2W) using individual patient data (IPD) from the ADvocate 1 and 2 monotherapy and using aggregate data from the adult-exclusive SOLO-CONTINUE trial for Dupilumab, published in the Dermatology and Therapy
- 08 Nov 2021 Results evaluating the patient perception of well-being and of treatment effect over 36 weeks of maintenance treatment with Dupilumab monotherapy every 2 weeks, presented at the 2021 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology.
- 14 Mar 2020 Results published in the European Clinical Trials Database Trial Registry